← Patent-cliff monitor A research-based biopharmaceutical company developing and commercializing medicines.
Company AngelList URL https://angel.co/gilead-sciences Blog http://www.gild.com/blog CAGE Code 0SFJ8 Legal Name Gilead Sciences, Inc. Company Operating Status Active Crunchbase URL https://www.crunchbase.com/organization/gilead-sciences Email format {first}.{last} Facebook URL https://www.facebook.com/GileadSciences
39 upcoming patent cliffs Drug Ingredient Type Cliff
VITEKTA ELVITEGRAVIR Small mol. Apr 2027 VITEKTA ELVITEGRAVIR Small mol. Apr 2027 ATRIPLA EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE Small mol. Apr 2029 SOVALDI SOFOSBUVIR Small mol. Jun 2031 SOVALDI SOFOSBUVIR Small mol. Jun 2031 SOVALDI SOFOSBUVIR Small mol. Jun 2031 SOVALDI SOFOSBUVIR Small mol. Jun 2031 LETAIRIS AMBRISENTAN Small mol. Oct 2031 LETAIRIS AMBRISENTAN Small mol. Oct 2031 Trodelvy sacituzumab govitecan-hziy Biologic Apr 2032 COMPLERA EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE Small mol. Jan 2033 ODEFSEY EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE Small mol. Feb 2033 VEMLIDY TENOFOVIR ALAFENAMIDE FUMARATE Small mol. Feb 2033 HARVONI LEDIPASVIR; SOFOSBUVIR Small mol. Mar 2033 HARVONI LEDIPASVIR; SOFOSBUVIR Small mol. Mar 2033 GENVOYA COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE Small mol. Apr 2033 STRIBILD COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE Small mol. Apr 2033 TYBOST COBICISTAT Small mol. Apr 2033 TYBOST COBICISTAT Small mol. Apr 2033 ZYDELIG IDELALISIB Small mol. Sep 2033 ZYDELIG IDELALISIB Small mol. Sep 2033 EPCLUSA SOFOSBUVIR; VELPATASVIR Small mol. Jul 2034 EPCLUSA SOFOSBUVIR; VELPATASVIR Small mol. Jul 2034 EPCLUSA SOFOSBUVIR; VELPATASVIR Small mol. Jul 2034 EPCLUSA SOFOSBUVIR; VELPATASVIR Small mol. Jul 2034 HARVONI LEDIPASVIR; SOFOSBUVIR Small mol. Jul 2034 HARVONI LEDIPASVIR; SOFOSBUVIR Small mol. Jul 2034 LIVDELZI SELADELPAR LYSINE Small mol. Mar 2035 DESCOVY EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE Small mol. Jun 2036 DESCOVY EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE Small mol. Jun 2036 BIKTARVY BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE Small mol. Nov 2036 BIKTARVY BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE Small mol. Nov 2036 VOSEVI SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR Small mol. Dec 2037 YEZTUGO LENACAPAVIR SODIUM Small mol. Aug 2038 YEZTUGO LENACAPAVIR SODIUM Small mol. Nov 2040 SUNLENCA LENACAPAVIR SODIUM Small mol. Aug 2041 SUNLENCA LENACAPAVIR SODIUM Small mol. Aug 2041 VEKLURY REMDESIVIR Small mol. Nov 2041 VEKLURY REMDESIVIR Small mol. Nov 2041 EMTRIVA EMTRICITABINE Small mol. — CAYSTON AZTREONAM Small mol. — VIREAD TENOFOVIR DISOPROXIL FUMARATE Small mol. — VISTIDE CIDOFOVIR Small mol. — EMTRIVA EMTRICITABINE Small mol. — HEPSERA ADEFOVIR DIPIVOXIL Small mol. — TRUVADA EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE Small mol. — TRUVADA EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE Small mol. — TRUVADA EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE Small mol. — TRUVADA EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE Small mol. — VIREAD TENOFOVIR DISOPROXIL FUMARATE Small mol. — VIREAD TENOFOVIR DISOPROXIL FUMARATE Small mol. — VIREAD TENOFOVIR DISOPROXIL FUMARATE Small mol. — VIREAD TENOFOVIR DISOPROXIL FUMARATE Small mol. — Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.